PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor

References

• Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol. 2017;19:v1–v88. doi: 10.1093/neuonc/nox158.
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–820. doi: 10.1007/s00401-016-1545-1.
   PubMed Web of Science ®Google Scholar
• Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang X, Jiang C, Kang C, Li X, Chen L, et al. CGCG clinical practice guidelines for the management of adult diffuse gliomas. Cancer Lett. 2016;375:263–273. doi: 10.1016/j.canlet.2016.01.024.
   PubMed Web of Science ®Google Scholar
• Yang P, Wang Y, Peng X, You G, Zhang W, Yan W, Bao Z, Wang Y, Qiu X, Jiang T. Management and survival rates in patients with glioma in China (2004–2010): a retrospective study from a single-institution. J Neurooncol. 2013;113:259–266. doi: 10.1007/s11060-013-1103-9.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998. doi: 10.1038/ni1102-991.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Reviews Clin Oncol. 2017. doi: 10.1038/nrclinonc.2017.101.
   PubMed Web of Science ®Google Scholar
• Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol. 2005;25:9543–9553. doi: 10.1128/MCB.25.21.9543-9553.2005.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chung Y, Bishop C, Daugherty B, Chute H, Holst P, Kurahara C, Lott F, Sun N, Welcher AA, et al. Regulation of T cell activation and tolerance by PDL2. Proc Natl Acad Sci U S A. 2006;103:11695–11700. doi: 10.1073/pnas.0601347103.
   PubMed Web of Science ®Google Scholar
• Singh AK, Stock P, Akbari O. Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy. 2011;66:155–162. doi: 10.1111/j.1398-9995.2010.02458.x.
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261–268. doi: 10.1038/85330.
   PubMed Web of Science ®Google Scholar
• Wang H, Yao H, Li C, Liang L, Zhang Y, Shi H, Zhou C, Chen Y, Fang J-Y, Xu J. PD-L2 expression in colorectal cancer: independent prognostic effect and targetability by deglycosylation. Oncoimmunology. 2017;6:e1327494. doi: 10.1080/2162402X.2017.1327494.
   PubMed Web of Science ®Google Scholar
• Howitt BE, Sun HH, Roemer MG, Kelley A, Chapuy B, Aviki E, Pak C, Connelly C, Gjini E, Shi Y, et al. Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva. JAMA oncol. 2016;2:518–522. doi: 10.1001/jamaoncol.2015.6326.
   PubMed Web of Science ®Google Scholar
• Shi M, Roemer MG, Chapuy B, Liao X, Sun H, Pinkus GS, Shipp MA, Freeman GJ, Rodig SJ. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014;38:1715–1723. doi: 10.1097/PAS.0000000000000297.
   PubMed Web of Science ®Google Scholar
• Karunarathne DS, Horne-Debets JM, Huang JX, Faleiro R, Leow CY, Amante F, Watkins TS, Miles JJ, Dwyer PJ, Stacey KJ, et al. Programmed Death-1 Ligand 2-Mediated regulation of the PD-L1 to PD-1 axis is essential for establishing CD4(+) T cell immunity. Immunity. 2016;45:333–345. doi: 10.1016/j.immuni.2016.07.017.
   PubMed Web of Science ®Google Scholar
• Liu X, Gao JX, Wen J, Yin L, Li O, Zuo T, Gajewski TF, Fu Y-X, Zheng P, Liu Y. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med. 2003;197:1721–1730. doi: 10.1084/jem.20022089.
   PubMed Web of Science ®Google Scholar
• Yan W, Zhang W, You G, Zhang J, Han L, Bao Z, Wang Y, Liu Y, Jiang C, Kang C, et al. Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese glioma cooperative group. Neuro Oncol. 2012;14:1432–1440. doi: 10.1093/neuonc/nos263.
   PubMed Web of Science ®Google Scholar
• Yan W, Zhang W, You G, Bao Z, Wang Y, Liu Y, Kang C, You Y, Wang L, Jiang T, et al. Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PloS one. 2012;7:e30339. doi: 10.1371/journal.pone.0030339.
   PubMed Web of Science ®Google Scholar
• Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765–773. doi: 10.1056/NEJMoa0808710.
   PubMed Web of Science ®Google Scholar
• Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res: an off J Am Assoc Cancer Res. 2017;23:3158–3167. doi: 10.1158/1078-0432.CCR-16-1761.
   PubMed Web of Science ®Google Scholar
• Erlmeier F, Weichert W, Autenrieth M, Wiedemann M, Schrader AJ, Hartmann A, Ivanyi P, Steffens S. PD-L2: A prognostic marker in chromophobe renal cell carcinoma? Med oncol. 2017;34:71. doi: 10.1007/s12032-017-0926-1.
   PubMed Web of Science ®Google Scholar
• Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res: BCR. 2009;11:R15. doi: 10.1186/bcr2234.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Meng F, Wang W, Wang Z, Zhang C, Jiang T. Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas. Sci data. 2017;4:170024. doi: 10.1038/sdata.2017.24.
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Hamilton RL. Molecular diagnostics of gliomas. Arch Pathol Lab Med. 2011;135:558–568.
   PubMed Web of Science ®Google Scholar
• Goswami KK, Ghosh T, Ghosh S, Sarkar M, Bose A, Baral R. Tumor promoting role of anti-tumor macrophages in tumor microenvironment. Cell Immunol. 2017;316:1–10. doi: 10.1016/j.cellimm.2017.04.005.
   PubMed Web of Science ®Google Scholar
• Liu S, Wang Y, Fan X, Ma J, Ma W, Wang R, Jiang T, Szele F. Anatomical involvement of the subventricular zone predicts poor survival outcome in low-grade astrocytomas. PloS one. 2016;11:e0154539. doi: 10.1371/journal.pone.0154539.
   PubMed Web of Science ®Google Scholar
• Li G, Wang Z, Zhang C, Liu X, Cai J, Wang Z, Hu H, Wu F, Bao Z, Liu Y, et al. Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. Oncoimmunology. 2017;6:e1328339. doi: 10.1080/2162402X.2017.1328339.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Wei J, Yaghi NK, Huang N, Kong L-Y, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18:195–205. doi: 10.1093/neuonc/nov172.
   PubMed Web of Science ®Google Scholar
• Xue S, Hu M, Iyer V, Yu J. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. J Hematol Oncol. 2017;10:81. doi: 10.1186/s13045-017-0455-6.
   PubMed Web of Science ®Google Scholar
• Li Y, Li F, Jiang F, Lv X, Zhang R, Lu A, Zhang G. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci. 2016;17. doi :10.3390/ijms17071151.
   Web of Science ®Google Scholar
• Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Reviews Immunol. 2015;15:45–56. doi: 10.1038/nri3790.
   PubMed Web of Science ®Google Scholar
• He YF, Zhang GM, Wang XH, Zhang H, Yuan Y, Li D, Feng Z-H. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J Immunol. 2004;173:4919–4928. doi: 10.4049/jimmunol.173.8.4919.
   PubMed Web of Science ®Google Scholar
• Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J Clin Oncol: off JAm Soc Clin Oncol. 2016;34:2690–2697. doi: 10.1200/JCO.2016.66.4482.
   PubMed Web of Science ®Google Scholar
• Dong M, Wang HY, Zhao XX, Chen J-N, Zhang Y-W, Huang Y, Xue L, Li H-G, Du H, Wu X-Y, et al. Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in epstein-barr virus-associated gastric carcinoma. Hum Pathol. 2016;53:25–34. doi: 10.1016/j.humpath.2016.02.007.
   PubMed Web of Science ®Google Scholar
• Nie X, Chen W, Zhu Y, Huang B, Yu W, Wu Z, Guo S, Zhu Y, Luo L, Wang S, et al. B7-DC (PD-L2) costimulation of CD4(+) T-helper 1 response via RGMb. Cell Mol Immunol. 2017. doi: 10.1038/cmi.2017.17.
   PubMed Web of Science ®Google Scholar
• Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res: an off J Am Assoc Cancer Res. 2005;11:2947–2953. doi: 10.1158/1078-0432.CCR-04-1469.
   PubMed Web of Science ®Google Scholar
• Masugi Y, Nishihara R, Hamada T, Song M, Da Silva A, Kosumi K, Gu M, Shi Y, Li W, Liu L, et al. Tumor PDCD1LG2 (PD-L2) expression and the lymphocytic reaction to colorectal cancer. Cancer Immunol Res. 2017;5:1046–1055. doi: 10.1158/2326-6066.CIR-17-0122.
   PubMed Web of Science ®Google Scholar
• Wang BJ, Bao JJ, Wang JZ, Wang Y, Jiang M, Xing M-Y, Zhang W-G, Qi J-Y, Roggendorf M, Lu M-J, et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol. 2011;17:3322–3329. doi: 10.3748/wjg.v17.i28.3322.
   PubMed Web of Science ®Google Scholar
• Takamura Y, Ikeda H, Kanaseki T, Toyota M, Tokino T, Imai K, Houkin K, Sato N. Regulation of MHC class II expression in glioma cells by class II transactivator (CIITA). Glia. 2004;45:392–405. doi: 10.1002/glia.10343.
   PubMed Web of Science ®Google Scholar
• Chang H, Kim JS, Choi YJ, Cho J-G, Woo J-S, Kim A, Kim JS, Kang EJ. Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. Onco Targets Ther. 2017;10:2983–2992. doi: 10.2147/OTT.S134589.
   PubMed Web of Science ®Google Scholar
• Disis ML. Immune regulation of cancer. J Clin Oncol: off JAm Soc Clin Oncol. 2010;28:4531–4538. doi: 10.1200/JCO.2009.27.2146.
   PubMed Web of Science ®Google Scholar
• Pandolfi F, Cianci R, Pagliari D, Casciano F, Bagalà C, Astone A, Landolfi R, Barone C. The immune response to tumors as a tool toward immunotherapy. Clin Dev Immunol. 2011;2011:894704. doi: 10.1155/2011/894704.
   PubMed Web of Science ®Google Scholar
• Tang Y, Xu X, Guo S, Zhang C, Tang Y, Tian Y, Ni B, Lu B, Wang H, Shiku H. An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PloS one. 2014;9:e91551. doi: 10.1371/journal.pone.0091551.
   PubMed Web of Science ®Google Scholar
• Comito G, Giannoni E, Segura CP, Barcellos-de-Souza P, Raspollini MR, Baroni G, Lanciotti M, Serni S, Chiarugi P. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene. 2014;33:2423–2431. doi: 10.1038/onc.2013.191.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10:942–949. doi: 10.1038/nm1093.
   PubMed Web of Science ®Google Scholar
• Okudaira K, Hokari R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C, Kurihara C, Kawaguchi A, Nagao S, Azuma M, et al. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol. 2009;35:741–749.
   PubMed Web of Science ®Google Scholar